CELLINK AB to Acquire GINOLIS OY – Major exit for Verso Fund II

CELLINK AB (publ) has entered into an agreement with the shareholders of Ginolis Oy to acquire all shares for a purchase price on cash- and debt-free basis of 70M euros (the “Acquisition”).

Ginolis Oy is a leading provider of robot-based automation solutions used world-wide to manufacture a variety of medical disposables and point-of-care tests such as Covid-19 tests.